ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 489

The Comparative Effectiveness of Anti-TNF Medications Among Older and Disabled Rheumatoid Arthritis Patients in the U.S. Medicare Population

Huifeng Yun1, Fenglong Xie2, Elizabeth S. Delzell3, Lang Chen4, Shuo Yang5, Kenneth G. Saag6 and Jeffrey R. Curtis7, 1Health Care Organization & Policy, University of Alabama-Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, 7Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Evaluating the real world effectiveness of biologic DMARDs in rheumatoid arthritis (RA) patients using administrative claims data has previously not been feasible due to the lack of clinical information present in such databases. A novel, recently published, validated administrative data-based algorithm (Curtis et. al., Arthritis Res Ther 2011) provides the potential to compare the effectiveness of different biologics to one another, with focus on older and vulnerable populations that are sometimes excluded or not present in large numbers in clinical trials or registries.

Methods: We evaluated the effectiveness of etanercept, adalimumab, and infliximab in 100% of Medicare beneficiaries with RA and with >= 24 months of fee-for-service + drug coverage, 2006-2009. Patients included those eligible for Medicare on the basis of age >= 65 or disability. New users of anti-TNF agents had a 12 month baseline during which no prescription or infusion of any biologic medication was given. The outcome was effectiveness at 12 +- 2 months according to the algorithm, which required six dichotomous conditions be met (Table).  We calculated the proportion meeting effectiveness criteria by anti-TNF medication and compared effectiveness between them using robust Poisson regression to compute risk ratios (RRs), adjusted for demographics, income, comorbidities and other medications.

Results: We identified 1,635, 2,077 and 3,181 new users of adalimumab, etanercept and infliximab, respectively. Overall, 35% of patients were disabled, almost all of whom were younger than age 65. The algorithm classified the medication as effective for 27% of adalimumab users, 31% of etanercept users, and 29% of infliximab users. After multivariable adjustment, the RRs for effectiveness were 0.99 (95% confidence interval (CI): 0.90-1.10) for adalimumab, and 1.11 (95% CI: 1.02-1.22) for etanercept compared to infliximab. Across all anti-TNFs, patients who were not disabled had higher effectiveness for anti-TNF medications than patients who were disabled (RR=1.26, 95% CI: 1.15-1.39).  

Conclusion:

A recently-published claims-based effectiveness algorithm provides opportunities to assess the comparative effectiveness of RA medications using administrative data.  Etanercept was associated with somewhat higher effectiveness among new anti-TNF users compared to infliximab. Effectiveness of all anti-TNF medications combined was significantly higher among older patients who were not disabled compared to younger, disabled RA patients.

Table: Components of the effectiveness algorithm†
for adalimumab, etanercept, and infliximab at 1 year *

 

Adalimumab  %

Etanercept

%

Infliximab %

Effectiveness Criteria, %

 

 

 

High adherence to the index drug

55

59

65

No switch to a different biologic

87

85

89

No addition of a new non-biologic DMARD

90

90

91

No biologic dose increase compared to starting dose

94

99

84

For patients not using glucocorticoids at baseline, no initiation of glucocorticoids; for patients using glucocorticoids at baseline, no increase in dose

84

88

84

No more than one joint injection on unique days after the 3 months of new treatments

89

90

88

Satisfied all 6 effectiveness criteria

27

31

29

†The gold standard outcome was low disease activity (Disease Activity Score using 28 joint counts (DAS28) <= 3.2) or improvement in DAS28 by >1.2 units at 12+2 months with high adherence to therapy. This newly published claims-based effectiveness algorithm was validated using the clinical information in Veterans affairs RA registry as the gold standard.

*assessed between the first exposure date and the outcome rheumatologist visit date (10-14 months later)

 


Disclosure:

H. Yun,

Amgen,

2;

F. Xie,
None;

E. S. Delzell,

Amgen,

2;

L. Chen,
None;

S. Yang,
None;

K. G. Saag,

AHRQ, NIH/NIAMS,

2,

Amgen;Abbott;Ardea:Lilly:Merck:Novartis:Regeneron:Savient:URL,

5,

NOF;ACR,

6;

J. R. Curtis,

Roche/Genetech, UCB< Centocor, Corrona,Amgen, Pfizer, BMS, Crescendo, Abbott, 2, Roche/Genetech,UCB, Centocor, CORRONA, Amgen, Pfizer, BMS, Crescendo, Abbott, 5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-comparative-effectiveness-of-anti-tnf-medications-among-older-and-disabled-rheumatoid-arthritis-patients-in-the-u-s-medicare-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology